TPR100 is a topical 1.86% diclofenac gel for pain relief that utilises Futura's DermaSys® technology. DermaSys® enables a fast onset of relief at the site of pain and the potential for improved patient benefit by reducing the dosing frequency to twice daily. In Europe Futura has partnered with Thornton & Ross, a STADA AG subsidiary, for the manufacturing and distribution of TPR100 in the UK. A marketing authorisation filing was submitted by Thornton and Ross in July 2018 and await responses and action from the UK regulator.